Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine

Contemporary Clinical Trials

Volumn 42, Issue , 2015, Pages 18-25

  Luxembourg, Alain ^a   Bautista, Oliver ^a   Moeller, Erin ^a   Ritter, Michael ^a   Chen, Joshua ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Clinical trial; Design; HPV; Papillomavirus; Vaccine

Indexed keywords

PLACEBO; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RISK REDUCTION; SEROTYPE; STUDY DESIGN; ADOLESCENT; ADULT; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; METHODOLOGY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; PHASE 3 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RESEARCH DESIGN; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84924709867     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.02.009     Document Type: Article

References (37)

1. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3):S11-S25.
2. Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl. 5):F12-F23.
3. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
4. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012, 7(1):38.
5. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
6. de Sanjose S., Alemany L., Ordi J., Tous S., Alejo M., Bigby S.M., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013, 49(16):3450-3461.
7. Alemany L., Saunier M., Alvarado-Cabrero I., Quiros B., Salmeron J., Shin H.R., et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2014, 136(1):98-107.
8. Alemany L., Saunier M., Tinoco L., Quiros B., Alvarado-Cabrero I., Alejo M., et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014, 50(16):2846-2854.
9. Joura E., Giuliano A., Iversen O.E., Bouchard C. 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015 Feb 19, 372(8):711-723.
10. Chen J., Gesser R., Luxembourg A. A seamless Phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials 2015 Feb, 12(1):84-90.
11. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30(Suppl. 5):F139-F148.
12. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
13. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
14. Stanley M., Pinto L.A., Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012, 30(Suppl. 5):F83-F87.
15. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV naive women aged 16-26. J Infect Dis 2009, 199(7):926-935.
16. Wellings K., Collumbien M., Slaymaker E., Singh S., Hodges Z., Patel D., et al. Sexual behaviour in context: a global perspective. Lancet 2006, 368(9548):1706-1728.
17. Koutsky L.A., Galloway D.A., Holmes K.K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988, 10:122-163.
18. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
19. Moscicki A.B., Schiffman M., Kjaer S., Villa L.L. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 2006, 24(Suppl. 3):S42-S51.
20. Massad L.S. Outcomes after diagnosis of vaginal intraepithelial neoplasia. J Low Genit Tract Dis 2008, 12(1):16-19.
21. van de Nieuwenhof H.P., van der Avoort I., de Hullu J.A. Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol 2008, 68(2):131-156.
22. Nobbenhuis M.A.E., Walboomers J.M.M., Helmerhorst T.J.M., et al. Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354:20-25.
23. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168(2):123-137.
24. Castle P.E., Rodriguez A.C., Burk R.D., Herrero R., Wacholder S., Alfaro M., et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009, 339:b2569.
25. Kjaer S.K., Frederiksen K., Munk C., Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102(19):1478-1488.
26. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007, 369:1693-1702.
27. World Health Organization Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. 57th Report Geneva 2006, WHO Expert Committee on Biological Standardization.
28. Roberts C., Hess E., Matys K., Brown M., Haupt R., Luxembourg A., et al. Development of a human papillomavirus competitive Luminex immunoassay for nine HPV types. Hum Vaccin Immunother 2014, 10(8):2174-103.
29. Chan I.S. Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies. Stat Med 1998, 17(12):1403-1413.
30. Chan I.S.F., Bohidar N.R. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Meth 1998, 27(6):1305-1322.
31. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Rozendaal L., Remmink A.J., Risse E.K.J., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278.
32. Wheeler C., Kjaer S.K., Sigurdsson K., Iversen O., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in sexually active women aged 16-26. J Infect Dis 2009, 199:936-944.
33. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092.
34. Powell S.E., Hariri S., Steinau M., Bauer H.M., Bennett N.M., Bloch K.C., et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012, 31(1):109-113.
35. Baldur-Felskov B., Dehlendorff C., Munk C., Kjaer S.K. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014, 106(3):djt460.
36. Crowe E., Pandeya N., Brotherton J.M., Dobson A.J., Kisely S., Lambert S.B., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014, 348:g1458.
37. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547.